Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Company profile
Ticker
GILD
Exchange
Website
CEO
Daniel O'Day
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GILEAD SCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Asegua Therapeutics LLC • Forty Seven, Inc. • Forty Seven Holdings, LLC • Gilead Alberta, LLC • Gilead Apollo, LLC • Gilead Biopharmaceutics US LLC • Gilead Calistoga, LLC • Gilead Connecticut, Inc. • Gilead Holdings, LLC • Gilead Pharmasset LLC ...
IRS number
943047598
GILD stock data
Latest filings (excl ownership)
8-K
Gilead Sciences Announces First Quarter 2024 Financial Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
8-K
Gilead Sciences Announces Completion of Acquisition of Cymabay
22 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
22 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
20 Mar 24
PRE 14A
Preliminary proxy
18 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
15 Mar 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
Transcripts
GILD
Earnings call transcript
2024 Q1
25 Apr 24
GILD
Earnings call transcript
2023 Q4
6 Feb 24
GILD
Earnings call transcript
2023 Q3
7 Nov 23
GILD
Earnings call transcript
2023 Q2
3 Aug 23
GILD
Earnings call transcript
2023 Q1
27 Apr 23
GILD
Earnings call transcript
2022 Q4
2 Feb 23
GILD
Earnings call transcript
2022 Q3
28 Oct 22
GILD
Earnings call transcript
2022 Q2
2 Aug 22
GILD
Earnings call transcript
2022 Q1
29 Apr 22
GILD
Earnings call transcript
2021 Q4
2 Feb 22
Latest ownership filings
SC 13G
LEAP THERAPEUTICS, INC.
19 Apr 24
3
LEAP THERAPEUTICS, INC.
19 Apr 24
SC 13G
Xilio Therapeutics, Inc.
5 Apr 24
4
Xilio Therapeutics, Inc.
3 Apr 24
3
Xilio Therapeutics, Inc.
3 Apr 24
4
Merdad Parsey
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Kevin E Lofton
29 Mar 24
4
Deborah H Telman
12 Mar 24
4
Sandra Patterson
12 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
61.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1462 |
Opened positions | 177 |
Closed positions | 359 |
Increased positions | 552 |
Reduced positions | 558 |
13F shares | Current |
---|---|
Total value | 57.61 tn |
Total shares | 761.61 mm |
Total puts | 3.68 mm |
Total calls | 2.31 mm |
Total put/call ratio | 1.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 111.82 mm | $9.06 tn |
Capital World Investors | 83.36 mm | $6.75 tn |
Capital Research Global Investors | 59.66 mm | $4.83 tn |
STT State Street | 59.54 mm | $4.82 tn |
Dodge & Cox | 33.30 mm | $2.70 tn |
Wellington Management | 18.63 mm | $1.51 tn |
MS Morgan Stanley | 17.80 mm | $1.44 tn |
FMR | 17.10 mm | $1.39 tn |
BK Bank Of New York Mellon | 15.50 mm | $1.26 tn |
NTRS Northern Trust | 14.03 mm | $1.14 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Gilead Sciences | Common Stock | Buy | Acquire P | No | No | 0.76 | 485,250 | 368.79 k | 7,345,473 |
2 Apr 24 | Gilead Sciences | Prefunded Warrants Common Stock | Buy | Acquire P | No | No | 0.7599 | 3,882,450 | 2.95 mm | 3,882,450 |
1 Apr 24 | Parsey Merdad | Common Stock | Sell | Dispose S | No | Yes | 72.96 | 2,000 | 145.92 k | 96,304 |
28 Mar 24 | Lofton Kevin E | Phantom Stock Common Stock | Grant | Acquire A | No | No | 0 | 33.893 | 0.00 | 3,258.139 |
News
Gilead Sciences Q1 2024 Adj EPS $(1.32) Beats $(1.49) Estimate, Sales $6.10B Miss $6.34B Estimate
25 Apr 24
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
25 Apr 24
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
25 Apr 24
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
25 Apr 24
HSBC Upgrades Gilead Sciences to Hold, Announces $69 Price Target
24 Apr 24
Press releases
Gilead Sciences Announces First Quarter 2024 Financial Results
25 Apr 24
Biotech Innovations Paving the Way in Breast Cancer Fight
11 Apr 24
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
8 Apr 24
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
28 Mar 24
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
28 Mar 24